Gilead Details Its HCV Dominance As AbbVie Seeks Meaningful Market Position
Executive Summary
Gilead holds a 90% market share in the U.S. hepatitis C market, with Harvoni capturing roughly 85% of the aggregate treatment population. AbbVie hopes an imminent Japanese approval and a second-generation regimen will boost its HCV business.